Published on
October 1, 2026
- 17:04 GMT
Opsin Biotherapeutics Awarded $2.35 Million NIH Grant to Advance Optogenetic Neuromodulation for Chronic Pain
Non-dilutive funding supports IND-enabling development of a cell-type-selective alternative to electrical neuromodulation. BEDFORD, TX, UNITED STATES, October 1, 2026 /EINPresswire.com/ -- Opsin Biotherapeutics, a pioneering biomedical technology …
Distribution channels:
Healthcare & Pharmaceuticals Industry, Science
...
